US 9593333
Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
granted A61KA61K31/7088A61K45/06
Quick answer
US patent 9593333 (Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations) held by Ionis Pharmaceuticals, Inc. expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/7088, A61K45/06, A61P, A61P1/18